Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Ulcerative Colitis: The First Multicenter Study in China
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Patients with active ulcerative colitis (UC) have elevated levels of activated myeloid-derived leukocytes as a source of inflammatory cytokines. The selective depletion of these leukocytes by adsorptive granulocyte/monocyte apheresis (GMA) with an Adacolumn should alleviate inflammation, promote remission and enhance drug efficacy. However, studies have reported contrasting efficacy outcomes based on patients’ baseline demographic variables. This study was undertaken to understand the demographic features of GMA responders and nonresponders. Methods: This was a multicenter study in China involving four institutions and 34 patients with active UC. Baseline conventional medications were continued without changing the dosage. The treatment efficacy was evaluated based on the endoscopic activity index and the Mayo score. Results: Thirty of the 34 patients completed all 10 GMA treatment sessions. The overall efficacy rate was 70.59%. The receiver operating characteristic analysis showed that the area under the curve was approximately 0.766 for a Mayo score of ≤5.5 with 0.273 specificity and 0.857 sensitivity (Youden index, 0.584) for GMA responders. No GMA-related serious adverse events were observed. Conclusions: The overall efficacy of GMA in patients with active UC who were taking first-line medications or were corticosteroid refractory was encouraging. Additionally, GMA was well tolerated and had a good safety profile.
Abstract
Background/Aims: Patients with active ulcerative colitis (UC) have elevated levels of activated myeloid-derived leukocytes as a source of inflammatory cytokines. The selective depletion of these leukocytes by adsorptive granulocyte/monocyte apheresis (GMA) with an Adacolumn should alleviate inflammation, promote remission and enhance drug efficacy. However, studies have reported contrasting efficacy outcomes based on patients’ baseline demographic variables. This study was undertaken to understand the demographic features of GMA responders and nonresponders. Methods: This was a multicenter study in China involving four institutions and 34 patients with active UC. Baseline conventional medications were continued without changing the dosage. The treatment efficacy was evaluated based on the endoscopic activity index and the Mayo score. Results: Thirty of the 34 patients completed all 10 GMA treatment sessions. The overall efficacy rate was 70.59%. The receiver operating characteristic analysis showed that the area under the curve was approximately 0.766 for a Mayo score of ≤5.5 with 0.273 specificity and 0.857 sensitivity (Youden index, 0.584) for GMA responders. No GMA-related serious adverse events were observed. Conclusions: The overall efficacy of GMA in patients with active UC who were taking first-line medications or were corticosteroid refractory was encouraging. Additionally, GMA was well tolerated and had a good safety profile.
참고문헌 (36)
- Conrad K, "Diagnosis and classification of ulcerative colitis", Autoimmun Rev, 13, pp.463~466 (2014)
- Podolsky DK, "Inflammatory bowel disease", N Engl J Med, 347, pp.417~429 (2002)
- Tominaga K, "Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone", BMC Gastroenterol, 13, pp.41~ (2013)
- Ken Fukunaga, "Adsorptive Granulocyte", Monocyte Apheresis for the Maintenance of Remission in Patients with Ulcerative Colitis: A Prospective Randomized, Double Blind, Sham-Controlled Clinical Trial, 2012, pp.6(4), 427~433[DOI]
- Tomomasa T, "Leukocytapheresis in pediatric patients with ulcerative colitis", J Pediatr Gastroenterol Nutr, 53, pp.34~39 (2011)
- Yamamoto T, "Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study", J Gastroenterol, 46, pp.1003~1009 (2011)
- Sakuraba A, "Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study", Ther Apher Dial, 16, pp.213~218 (2012)
- Okuyama Y, "Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis", Scand J Gastroenterol, 48, pp.412~418 (2013)
- Saniabadi AR, "Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy", J Clin Apher, 20, pp.171~184 (2005)
- Inoue T, "The efficacy of oral tacrolimus in patients with moderate", severe ulcerative colitis not receiving concomitant corticosteroid therapy, 2013, pp.52, 15~20
- Sakata Y, "Comparison of the efficacy of granulocyte and monocyte", macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients:a prospective randomized study, 2008, pp.20, 629~633
- Yokoyama Y, "Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA", BMC Gastroenterol, 13, pp.27~ (2013)
- Passalacqua S, "The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study", J Clin Apher, 26, pp.332~337 (2011)
- Takahashi H, "Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients", Arch Gynecol Obstet, 288, pp.341~347 (2013)
- Rosenberg L, "Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission", Inflamm Bowel Dis, 19, pp.779~784 (2013)
- Tanaka T, "Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications", BMC Gastroenterol, 13, pp.130~ (2013)
- Suzuki Y, "Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study", Dig Dis Sci, 49, pp.565~571 (2004)
- Noguchi A, "The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity", J Gastroenterol, 42, pp.947~956 (2007)
- Isomoto H, "Magnifying endoscopic findings can predict clinical outcome during long-term follow-up of more than 12 months in patients with ulcerative colitis", Gastroenterol Res Pract, 2013, pp.671576~ (2013)
- Yoshida A, "Possible role of early transabdominal ultrasound in patients undergoing cytapheresis for active ulcerative colitis", Intern Med, 50, pp.11~15 (2011)
- Cabriada JL, "Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry", J Gastroenterol, 47, pp.359~365 (2012)
- Naganuma M, "Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients", J Gastroenterol, 45, pp.936~943 (2010)
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
- Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study", N Engl J Med, 317, pp.1625~1629 (1987)
- Hu PJ, "The consensus for the diagnosis and treatment of inflammatory bowel disease", Chin J Dig, 32, pp.796~813 (2012)
- Amarender Singh Puri, "Epidemiology of Ulcerative Colitis in South Asia", Intestinal research, 11(4), pp.250~255 (2013), 대한장연구학회
- Yoshino T, "Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants", Digestion, 84, pp.3~9 (2011)
- Yokoyama Y, "Crohn’s disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile", Cytotherapy, 16, pp.821~825 (2014)
- Saniabadi AR, "Therapeutic leukocytapheresis for inflammatory bowel disease", Transfus Apher Sci, 37, pp.191~200 (2007)
- Suzuki Y, "A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis", Dig Dis Sci, 51, pp.2031~2038 (2006)
- Tanaka T, "In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients", Dig Liver Dis, 40, pp.731~736 (2008)
- Yokoyama Y, "Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study", Cytotherapy, 17, pp.680~688 (2015)
- Saniabadi AR, "Treating inflammatory bowel disease by adsorptive leucocytapheresis:a desire to treat without drugs", World J Gastroenterol, 20, pp.9699~9715 (2014)
- Sacco R, "Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders", Expert Rev Gastroenterol Hepatol, 9, pp.327~333 (2015)
- Sands BE, "A randomized, doubleblind, sham-controlled study of granulocyte", monocyte apheresis for active ulcerative colitis, 2008, pp.135, 400~409
- Yamamoto T, "Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis", J Crohns Colitis, 6, pp.750~755 (2012)